Duration of Protection and Age-Dependence of the Effects of the SPf66 Malaria Vaccine in African Children Exposed to Intense Transmission of Plasmodium falciparum

The SPf66 synthetic vaccine is safe and partly efficacious against Plasmodium falciparum malaria among children 1–5 years old. The estimated vaccine efficacy [VE] for all clinical episodes over a period of 18 months after the third dose is 25% (95% confidence interval [CI], 1%–44%; P = .044). The ob...

Full description

Saved in:

Bibliographic Details
Published in:	The Journal of infectious diseases Vol. 174; no. 2; pp. 367 - 372
Main Authors:	Alonso, Pedro L., Smith, Tom A., Armstrong-Schellenberg, Joanna R. M., Kitua, Andrew Y., Masanja, Honorathi, Hayes, Richard, Hurt, Nicole, Font, Fidel, Menendez, Clara, Kilama, Wencislaus L., Tanner, Marcel
Format:	Journal Article
Language:	English
Published:	Chicago, IL The University of Chicago Press 01-08-1996 University of Chicago Press Oxford University Press
Subjects:	Age Factors Age groups Biological and medical sciences Child, Preschool Children Cross-Sectional Studies Dosage Epidemiology Experimentation Follow-Up Studies Human protozoal diseases Humans Incidence Infant Infectious diseases Major Articles Malaria Malaria vaccine Malaria Vaccines - therapeutic use Malaria, Falciparum - blood Malaria, Falciparum - epidemiology Malaria, Falciparum - prevention & control Malaria, Falciparum - transmission Medical sciences Parasites Parasitic diseases Placebos Plasmodium falciparum Population Surveillance Protozoal diseases Protozoan Proteins - therapeutic use Recombinant Proteins Tanzania - epidemiology Time Factors Tropical medicine Vaccination Vaccines, Synthetic - therapeutic use Africa Tanzania Human Protozoa Protozoal disease Malaria Treatment efficiency Vaccine Parasitosis Infection Immunoprophylaxis Plasmodium falciparum Immunogenicity Sporozoa Child Age
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	The SPf66 synthetic vaccine is safe and partly efficacious against Plasmodium falciparum malaria among children 1–5 years old. The estimated vaccine efficacy [VE] for all clinical episodes over a period of 18 months after the third dose is 25% (95% confidence interval [CI], 1%–44%; P = .044). The observed temporal variations in efficacy could have been due to chance (likelihood ratio χ2 = 13.8,8 df; P = .086). Efficacy against clinical malaria did not vary significantly with age χ2 = 1.07, 4 df; P = .90). Overall parasite density was 21% lower in vaccine recipients than in the placebo group (95% CI, 0%–38%; P = .044). Further development of SPf66 may require trials to evaluate safety, immunogenicity, and efficacy when administered in the first year of life, together with other vaccines contained in the Expanded Programme of Tmmunization schedule.
Bibliography:	Reprints or correspondence: Dr. P. L. Alonso, Unidad de Epidemiologia y Bioestadistica, Hospital Clinic, Villarroel 170, E-08036 Barcelona, Spain. istex:7679335542F2FF8E7B6A65D6DF724E89C4EDCAC2 ark:/67375/HXZ-K1VZRJXF-X ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23
ISSN:	0022-1899 1537-6613
DOI:	10.1093/infdis/174.2.367